RU96109376A - CONNECTIONS FOR USE IN MEDICINE - Google Patents
CONNECTIONS FOR USE IN MEDICINEInfo
- Publication number
- RU96109376A RU96109376A RU96109376/14A RU96109376A RU96109376A RU 96109376 A RU96109376 A RU 96109376A RU 96109376/14 A RU96109376/14 A RU 96109376/14A RU 96109376 A RU96109376 A RU 96109376A RU 96109376 A RU96109376 A RU 96109376A
- Authority
- RU
- Russia
- Prior art keywords
- acetylmuramyl
- alanyl
- acetyl
- glucosaminyl
- use according
- Prior art date
Links
- 125000000539 amino acid group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 5
- 239000004472 Lysine Substances 0.000 claims 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 3
- -1 D-isoglutaminyl Chemical group 0.000 claims 2
- 210000000981 Epithelium Anatomy 0.000 claims 2
- PIJXCSUPSNFXNE-QRZOAFCBSA-N N-acetyl-4-(N-acetylglucosaminyl)muramoyl-L-alanyl-D-isoglutamine Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]1[C@@H](NC(C)=O)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 PIJXCSUPSNFXNE-QRZOAFCBSA-N 0.000 claims 2
- 208000006994 Precancerous Condition Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000000699 topical Effects 0.000 claims 2
- FKHUGQZRBPETJR-RXSRXONKSA-N (2R)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 229960003767 Alanine Drugs 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical group OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims 1
- 125000004077 D-glutamic acid group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(N([H])[H])=O 0.000 claims 1
- 208000007276 Esophageal Squamous Cell Carcinoma Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 208000008025 Hordeolum Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims 1
- VYZAGTDAHUIRQA-CRCLSJGQSA-N L-alanyl-D-glutamic acid Chemical compound C[C@H](N)C(=O)N[C@@H](C(O)=O)CCC(O)=O VYZAGTDAHUIRQA-CRCLSJGQSA-N 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 1
- 229950009571 MURABUTIDE Drugs 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 210000002200 Mouth Mucosa Anatomy 0.000 claims 1
- 210000004400 Mucous Membrane Anatomy 0.000 claims 1
- 125000003686 N-acetyl-D-glucosaminyl group Chemical group C(C)(=O)N[C@H]1C(O[C@@H]([C@H]([C@@H]1O)O)CO)* 0.000 claims 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 210000003899 Penis Anatomy 0.000 claims 1
- 102100011271 Phagocytosis-stimulating peptide Human genes 0.000 claims 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 1
- 229940035670 Tuftsin Drugs 0.000 claims 1
- 108010084754 Tuftsin Proteins 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N [(2R)-3-[2-[[(2S)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]propanoyl]amino]ethoxy-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] hexad Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 230000002378 acidificating Effects 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- ZDSXRJABOCTJTD-MLRLIGJLSA-N butyl (2R)-2-[[(2R)-2-[[(2S)-2-[3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoate Chemical compound CCCCOC(=O)[C@@H](CCC(N)=O)NC(=O)[C@@H](C)NC(=O)[C@H](C)OC1C(O)C(CO)OC(O)C1NC(C)=O ZDSXRJABOCTJTD-MLRLIGJLSA-N 0.000 claims 1
- ZDSXRJABOCTJTD-HUYBTDLASA-N butyl (2R)-2-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoate Chemical compound CCCCOC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O ZDSXRJABOCTJTD-HUYBTDLASA-N 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- CKTNHGVJKUQEBM-UHFFFAOYSA-N ethylazanide Chemical class CC[NH-] CKTNHGVJKUQEBM-UHFFFAOYSA-N 0.000 claims 1
- 125000005469 ethylenyl group Chemical group 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960005225 mifamurtide Drugs 0.000 claims 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229950003733 romurtide Drugs 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000000439 tumor marker Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (25)
в которой R1 представляет собой атом водорода или C1 - C22-ацильную группу;
R2 представляет собой атом водорода или C1 - C22-ацильную группу;
R3 представляет собой атом водорода C1 - C6-алкильную группу;
R4 представляет собой C1 - C21-алкильную группу или C6 или C10-арильную группу;
R5 представляет собой атом водорода;
R представляет собой остаток аминокислоты или линейный пептид, построенный из 2 - 6 кислотных остатков, причем по меньшей мере один из этих остатков необязательно замещен липофильной группой.8. The use according to any one of paragraphs.1 to 7, where muramylpeptide is a compound of General formula I
in which R 1 represents a hydrogen atom or a C 1 - C 22 -acyl group;
R 2 represents a hydrogen atom or a C 1 - C 22 -acyl group;
R 3 represents a hydrogen atom, a C 1 - C 6 alkyl group;
R 4 represents a C 1 - C 21 -alkyl group or a C 6 or C 10 -aryl group;
R 5 represents a hydrogen atom;
R is an amino acid residue or a linear peptide constructed from 2 to 6 acidic residues, and at least one of these residues is optionally substituted by a lipophilic group.
в которой R представляет собой остаток аминокислоты или линейный пептид, построенный из 2 - 6 аминокислотных остатков, причем по меньшей мере один из этих остатков необязательно замещен липофильной группой;
n = 1 или 2,
или его аномер.11. The use according to any one of paragraphs.1 to 7, where muramylpeptide compound is a compound of General formula II
in which R is an amino acid residue or a linear peptide constructed from 2 to 6 amino acid residues, and at least one of these residues is optionally substituted by a lipophilic group;
n = 1 or 2,
or its anomer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9320820.5 | 1993-10-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU96109376A true RU96109376A (en) | 1998-09-27 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6399568B1 (en) | Cyclic tetrapeptide derivatives and medicinal use thereof | |
AU666890B2 (en) | Muramyl compounds for treatment of septic shock | |
CS199673B2 (en) | Method of producing polypeptides | |
EP0748226A1 (en) | Block copolymers | |
JPS6227079B2 (en) | ||
JP3954644B2 (en) | Compounds used in medicine | |
JPH0680079B2 (en) | Polypeptide | |
KR900003205A (en) | Pharmaceutical compound | |
RU2016110153A (en) | New peptides and their analogues for use in the treatment of oral mucositis | |
US4010149A (en) | Analogs of LH-RH and process for preparing the same | |
RU96109376A (en) | CONNECTIONS FOR USE IN MEDICINE | |
EP0353565A1 (en) | Immunostimulating peptides, a process for their preparation and pharmaceutical commpositions containing them | |
PT87857B (en) | METHOD FOR PREPARING NEW PEPTIDES WITH IMMUNOSUPPRESSIVE PROPERTIES | |
KR960013387B1 (en) | Gonado liberine analogs with improved solubility, process for their preparation, agents containing then and their sue | |
Meller et al. | The human sodium-iodine symporter (NIS) as a key for specific thymic iodine-131 uptake | |
KR920701244A (en) | Ventricular Peptide Derivatives | |
KR100255526B1 (en) | Partially modified and retro-inverted tetrapeptides analogues of c-reactive protein fragments | |
EP0503044A1 (en) | Peptide compounds of laevorotatory amino acids and ring molecules, and therapeutical applications thereof. | |
JPH0363559B2 (en) | ||
JP3190765B2 (en) | Peptide derivatives and their uses | |
KR790001842B1 (en) | Process for producing novel polypeptides | |
KITAGAWA et al. | Alternative Synthesis of Substance P | |
KR790001841B1 (en) | Process for producing novel polypeptides | |
JPH0717999A (en) | Peptide derivative and use thereof | |
CA2142394A1 (en) | Organic compounds |